ホーム>>Signaling Pathways>> Immunology/Inflammation>> NF-κB>>Benzoyloxypaeoniflorin

Benzoyloxypaeoniflorin

カタログ番号GC35494

Paeonia suffruticosa の根から分離されたベンゾイルオキシペオニフロリンは、キノコのチロシナーゼに対するチロシナーゼ阻害剤であり、IC50 は 0.453 mM です。

Products are for research use only. Not for human use. We do not sell to patients.

Benzoyloxypaeoniflorin 化学構造

Cas No.: 72896-40-3

サイズ 価格 在庫数 個数
1mg
$112.00
在庫あり
5mg
$468.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Benzoyloxypaeoniflorin, isolated from the root of Paeonia suffruticosa, is a tyrosinase inhibitor against mushroom tyrosinase with IC50 of 0.453 mM. Benzoyloxypaeoniflorin is NF-κB Inhibitor and contributes to improving blood circulation through its inhibitory effect on both platelet aggregation and blood coagulation[1][2][3]. IC50: 0.453 mM (Mushroom tyrosinase)[1]NF-κB[2]

[1]. Ding HY, et al. Tyrosinase inhibitors isolated from the roots of Paeonia suffruticosa. J Cosmet Sci. 2009 May-Jun;60(3):347-52. [2]. Lu Y, et al. The Screening Research of NF-κB Inhibitors from Moutan Cortex Based on Bioactivity-Integrated UPLC-Q/TOF-MS. Evid Based Complement Alternat Med. 2019 Mar 3;2019:6150357. [3]. Koo YK, et al. Platelet anti-aggregatory and blood anti-coagulant effects of compounds isolated from Paeonia lactiflora and Paeonia suffruticosa. Pharmazie. 2010 Aug;65(8):624-8.

レビュー

Review for Benzoyloxypaeoniflorin

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Benzoyloxypaeoniflorin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.